Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Type 2 Diabetes Mellitus: KOL Insight [2017]

Product Code:
596200872
Publication Date:
September 2017
Format:
PDF + PPTX
Price:
£6,795

Will novel therapies transform the treatment of type 2 diabetes?

The treatment of type 2 diabetes mellitus has evolved in recent years with introduction of new classes of molecules. While the wide array of treatment options – including SGLT-2 inhibitors, GLP-1 agonists and newer insulin therapies – provide individualised therapy, unmet needs persist in the market for effective modalities that can provide optimal glycaemic control. Diabetes has a rich late-stage pipeline, but which candidates stand out to key opinion leaders (KOLs)? Which products and combinations are likely to succeed?

Learn how KOLs see the type 2 diabetes market evolving in KOL Insight: Type 2 Diabetes. Twelve US and European KOLs provide candid insights on 18 marketed and 11 pipeline therapies targeting various aspects of the type 2 diabetes treatment algorithm.

Download sample pages

Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!

Top takeaways

  • Can Lilly’s once-weekly Trulicity replace Novo Nordisk’s once-daily Victoza as the GLP-1 of choice? Victoza enjoys the dominant position in this class but can newer entrants challenge its dominance?
  • Can Novo Nordisk’s Xultophy and Sanofi’s Soliqua 100/33, embed themselves in treatment strategy? How do KOLs view these novel once-daily GLP-1/basal insulin combinations?
  • What do KOLs think of heart failure warnings for AstraZeneca’s Onglyza and Takeda’s Nesina? Do KOLs think signal could be a class-wide effect for DPP-4 inhibitors?
  • Is there a future for Takeda’s Oseni (alogliptin/pioglitazone) and Kazano (alogliptin/metformin) FDCs? How do KOLs see Oseni’s potential and can Kazano compete with Merck & Co.’s Janumet (sitagliptin/metformin)?
  • Following positive EMPA-REG OUTCOME data for Boehringer Ingelheim and Eli Lilly’s empagliflozin (Jardiance) can SGLT2 inhibitors move up in the treatment strategy? Can AstraZeneca’s dapagliflozin (Farxiga) compete with Jardiance?
  • How do KOLs view the novel SGLT2/DPP-4s combinations? Will Glyxambi (empagliflozin/linagliptin; Boehringer Ingelheim/Eli Lilly) and Qtern (dapagliflozin/saxagliptin; AstraZeneca) gain traction in the market?
  • What potential do KOLs think Novo Nordisk’s basal insulin degludec (Tresiba) and rapid-acting insulin aspart (Fiasp) and basal insulin degludec (Ryzodeg) have? What barriers do they need to be overcome?
  • How do KOLs rate Novo Nordisk’s injectable once-weekly semaglutide and Intarcia’s ITCA 650 implant? What challenges do KOLs see for these products?
  • Could Sanofi’s sotagliflozin, Theracos’ bexagliflozin and Pfizer/Merck & Co.’s ertugliflozin provide benefit? Pipeline SGLT2 inhibitors are entering a crowded market, so how do KOLs view their chances of success?
  • What do KOLs think about Roche’s sinogliatin, a fourth-generation glucokinase activator? How do experts rate this novel mechanism of action in diabetes?
  • Will PhaseBio’s Insumera provide an attractive proposition or pose more problems than solutions? What do KOLs think of the longer-acting insulin product?
Request sample pages

Back to the top

Quotes

“I hope there are more comparative studies. They are badly needed; we need to know what kind of drugs work better compared to the others. And more cardiovascular outcome studies, they are even more important than producing ten more drug classes. That’s how I see it.”
EU Key Opinion Leader

“We had some significant changes in the past decade with a lot of new categories of molecules and they are going to be part of routine diabetes care in the future. We may see some new drugs which will be competitors to metformin.”
EU Key Opinion Leader

Sample of therapies covered

Marketed Therapies

  • Farxiga/Forxiga (AstraZeneca/Bristol-Myers Squibb)
  • Fiasp (Novo Nordisk)
  • Glyxambi (Boehringer Ingelheim/Eli Lilly)
  • Invokana (Johnson & Johnson)
  • Jardiance (Boehringer Ingelheim)
  • Lyxumia/Adlyxin (Sanofi)
  • Nesina/Vipidia (Takeda)
  • Onglyza (AstraZeneca)
  • Qtern (AstraZeneca)
  • Ryzodeg (Novo Nordisk)
  • Synjardy (Boehringer Ingelheim)
  • Tanzeum/ Eperzan (GlaxoSmithKline)
  • Toujeo/Optisulin (Sanofi)
  • Tradjenta/Trajenta (Boehringer Ingelheim/Eli Lilly)
  • Tresiba (Novo Nordisk)
  • Trulicity (Eli Lilly)
  • Xultophy/IDegLira (Novo Nordisk)
  • Zafatek (Takeda/Furiex)

Pipeline Therapies

  • Atorvastatin/glimepiride (GlaxoSmithKline)
  • Bexagliflozin (Theracos)
  • Canagliflozin/teneligliptin (Mitsubishi Tanabe/Daiichi Sankyo)
  • Ertugliflozin (Pfizer/Merck & Co.)
  • Insumera (PhaseBio)
  • Ipragliflozin/sitagliptin (Astellas/Kotobuki/Merck & Co.)
  • ITCA 650 (Intarcia Therapeutics)
  • Pioglitazone/linagliptin (Boehringer Ingelheim)
  • Semaglutide (Novo Nordisk)
  • Sinogliatin (Roche/Hua Medicine)
  • Sotagliflozin (Lexicon/Sanofi)

KOLs interviewed

KOLs from North America

  • Prof. Vivian A. Fonseca, MD, FRCP. Chief, Section of Endocrinology, School of Medicine, Tulane University, New Orleans, LA
  • Prof. Osama Hamdy, MD, PhD, FACE. Medical Director/Clinical Investigator, Joslin Diabetes Center, Harvard Medical School, Boston, MA
  • David B. Jack, MD, FAAFP. Adjunct Clinical Faculty, University of Utah School of Medicine and Chair, Board of Trustees, Lone Peak Hospital, Draper, UT
  • Dr. Udaya M. Kabadi, MD. VA Medical Center, Central Iowa Healthcare System, Des Moines, IA
  • Dr. Michael Shanik, MD. Endocrinology Diabetes & Metabolism, Catherine of Siena Medical Center and St. Charles Hospital, Smithtown, NY
  • Prof. Vijay Shivaswamy, MD. Department of Internal Medicine, University of Nebraska Medical Center College of Medicine,Omaha, NE

KOLs from Europe

  • Prof. Pierre Yves Benhamou, MD, PhD. Professor of Endocrinology and Metabolism, and Head, Clinique d’Endocrinology Diabétology Nutrition, Pôle DIGIDUNE CHU de Grenoble, Université Joseph Fourier, Grenoble, France
  • Dr Federico Bertuzzi, MD. Medical Director and Consultant, Azienda Ospedaliera Niguarda Ca’ Granda - Unità di diabetologia, Milan, Italy
  • Prof. Fernando Gomez-Peralta, MD, PhD. Endocrinology and Nutrition Unit, Hospital General De Segovia , Segovia, Spain
  • Professor Richard Holt MA, MB, BChir, PhD, FRCP, FHEA. Professor in Diabetes and Endocrinology, Department of Medicine, University of Southampton, Southampton, UK
  • Dr Peter Winocour, MD, FRCP. Consultant Physician, Clinical Director, East and North Hertfordshire NHS Trust, Lister Hospital, Stevenage, UK
  • German KOL (Anonymous). Prof. Dr. med. and leading diabetologist in Germany

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.



customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved